FDA Grants Orphan Drug Designation to Crinetics’ Atumelnant for Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to atumelnant, its once-daily oral ACTH receptor…
Read More...
Read More...
